Recent trends in aerosol therapy for allergic rhinitis.
By analysing patients who visited our out-patient clinic during 4 years (1980-1983), it was found that 18.1% of total patients were suffering from allergic rhinitis. We also analysed prescriptions for allergic rhinitis and it was found that sodium cromoglycate was administered to about 50% of the patients and was the main therapy not only in aerosol type therapy but also in all therapies used for allergic rhinitis. In particular, sodium cromoglycate was administered to over 50% of pediatric patients. Sodium cromoglycate was administered alone in nearly 50% of the patients who used sodium cromoglycate. Accordingly, it can be said that about 25% of all patients were controlled by sodium cromoglycate alone. Steroid aerosol therapy was given to 30-40% of all allergic rhinitis patients. This was mainly due to a rapid increase of usage of beclomethasone dipropionate after 1982 when this was launched. Beclomethasone dipropionate was mainly used for adults patients and was used about 10% of pediatric patients.
Saito
Y
Y
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000336:Aerosols; D002648:Child; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; D000336:Aerosols; D004205:Cromolyn Sodium